Acquisition adds Key Offerings to Molecular Diagnostics Base

Finnish business Medix Biochemica has broadened its portfolio of molecular diagnostic raw materials for the in vitro diagnostics industry, through the acquisition of myPOLS Biotec which will continue with its operations in Konstanz, Germany.  Forming a significant part of the newly established Molecular Diagnostics Business Unit within the parent group, all founders of myPOLS Biotec remain involved in the business.

“This acquisition is a great step towards our vision to be the first-choice, independent raw material partner for the IVD industry and it further accelerates Medix Biochemica’s growth in molecular diagnostics reagents business which is a key strategic expansion area for us. The broad portfolio of myPOLS Biotec, including unique and innovative molecular diagnostics reagents, complements Medix Biochemica’s existing molecular diagnostics offering. With myPOLS technology, we enable customers to shorten their assay development time and complexity and perform molecular testing directly from crude samples. We will offer more flexibility in assay development by partnering in custom development projects. We are excited about the opportunity to offer these molecular diagnostics products to our global customer base,” said Steve Ferguson, CEO of Medix Biochemica.

“We are thrilled to join Medix Biochemica Group,” commented Dr. Ramon Kranaster, CEO of myPOLS Biotec. “We are looking forward to contributing to the strong growth of Medix Biochemica and we appreciate its clear focus on quality and R&D. The high scientific competence of the myPOLS team including best-in-class DNA polymerases, supports Medix Biochemica’s long term vision and focus on IVD customers’ needs.”

More information online